Uniqure N.V. (QURE) Stock Price, Quote & News

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 20 240 6000

Website: www.uniqure.com

Address:

Paasheuvelweg 25, Amsterdam, Netherlands

Wrangler4 Jun. 25 at 11:09 AM

$QURE Matt Kapusta at his next failed biotech conference. Peanuts , peanuts anyone …

0 · Reply

Wrangler4 Jun. 24 at 8:31 PM

$QURE More BS from the Matt Kapusta peanut gallery This stock is dog siht

0 · Reply

INandAROUNDandOUT Jun. 24 at 8:01 PM

$QURE Get its rhythm and trade its wide range as it moves up slow and steady.

0 · Reply

Jadek6 Jun. 24 at 6:14 PM

$QURE OH YES MAN 🥳🥳🥳🥳🎊🎉🎊

0 · Reply

HrSbdaddy Jun. 24 at 1:37 PM

$QURE Trash stock

0 · Reply

Wrangler4 Jun. 24 at 12:07 PM

$QURE Wainwright …$70 ..hahahaha She knows !!!

0 · Reply

Wrangler4 Jun. 24 at 10:22 AM

$CADL $QURE A new Day …New Con-ned-testants coming to see the TAK on the Flying Trapeze !!!

0 · Reply

Wrangler4 Jun. 23 at 5:24 PM

$CADL $QURE ..and !!!

0 · Reply

Wrangler4 Jun. 23 at 4:05 PM

$QURE $70 right wainwright , hahahaha sure it wasn’t a dyslexic analyst, lol and $7IS the real PT Wainwright is known for fcuking up !!

0 · Reply

Wrangler4 Jun. 23 at 4:00 PM

$QURE Hahahaaha ..MATT STRIKES ONCE AGAIN

0 · Reply

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

Jun 2, 2025, 7:05 AM EDT - 23 days ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

May 28, 2025, 4:56 AM EDT - 4 weeks ago

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

May 19, 2025, 8:00 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX CRBP

May 9, 2025, 10:16 PM EDT - 6 weeks ago

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:05 AM EDT - 6 weeks ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 8, 2025, 5:16 AM EDT - 6 weeks ago

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

May 5, 2025, 4:05 PM EDT - 7 weeks ago

uniQure to Announce First Quarter 2025 Financial Results

Apr 21, 2025, 1:56 AM EDT - 2 months ago

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

Apr 19, 2025, 8:31 AM EDT - 2 months ago

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Apr 17, 2025, 10:27 AM EDT - 2 months ago

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

Apr 17, 2025, 7:17 AM EDT - 2 months ago

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

Feb 27, 2025, 7:05 AM EST - 4 months ago

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

Feb 26, 2025, 1:47 AM EST - 4 months ago

uniQure N.V.: A Potential Huntington's Play

Feb 20, 2025, 3:07 PM EST - 4 months ago

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

Feb 7, 2025, 1:04 PM EST - 4 months ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Feb 7, 2025, 9:12 AM EST - 4 months ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Feb 3, 2025, 7:05 AM EST - 5 months ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Jan 30, 2025, 7:37 AM EST - 5 months ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Jan 8, 2025, 7:05 AM EST - 6 months ago

uniQure Announces Pricing of its Public Offering

Jan 7, 2025, 4:49 PM EST - 6 months ago

uniQure Announces Proposed Public Offering

Dec 30, 2024, 6:31 PM EST - 6 months ago

Final Trade: DVN, QURE, GOOGL, DFH

GOOG GOOGL DFH DVN

Dec 10, 2024, 7:05 AM EST - 7 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

$uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy$